Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares IssuedShort-Term Debt repayments
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gain Therapeutics (GANX) Change in Acquisitions & Divestments (2022 - 2024)

Historic Change in Acquisitions & Divestments for Gain Therapeutics (GANX) over the last 3 years, with Q4 2024 value amounting to -$42502.0.

  • Gain Therapeutics' Change in Acquisitions & Divestments fell 10135.28% to -$42502.0 in Q4 2024 from the same period last year, while for Dec 2024 it was $5.0 million, marking a year-over-year decrease of 5899.75%. This contributed to the annual value of $5.0 million for FY2024, which is 5899.75% down from last year.
  • According to the latest figures from Q4 2024, Gain Therapeutics' Change in Acquisitions & Divestments is -$42502.0, which was down 10135.28% from $2.0 million recorded in Q2 2024.
  • In the past 5 years, Gain Therapeutics' Change in Acquisitions & Divestments registered a high of $4.1 million during Q1 2023, and its lowest value of -$42502.0 during Q4 2024.
  • Its 3-year average for Change in Acquisitions & Divestments is $2.4 million, with a median of $2.5 million in 2022.
  • In the last 5 years, Gain Therapeutics' Change in Acquisitions & Divestments surged by 5144.87% in 2023 and then tumbled by 10135.28% in 2024.
  • Gain Therapeutics' Change in Acquisitions & Divestments (Quarter) stood at $2.1 million in 2022, then skyrocketed by 51.45% to $3.1 million in 2023, then tumbled by 101.35% to -$42502.0 in 2024.
  • Its Change in Acquisitions & Divestments was -$42502.0 in Q4 2024, compared to $2.0 million in Q2 2024 and $3.0 million in Q1 2024.